Cabaletta Bio (CABA) provided updates for CABA-201, saying that two out of four pemphigus vulgaris patients treated with CABA-201 without preconditioning chemo achieved virtually complete and durable remissions, Cantor Fitzgerald tells investors in a research note. The firm, which has an Overweight rating and $30 price target on the shares, says concerns regarding a financing overhang should be meaningfully addressed with the $150M offering in addition to the $135M on its balance sheet and $120M from warrant exercises.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CABA:
- Cabaletta Bio Announces $150 Million Equity Offering
- Cabaletta Bio reports promising RESET-PV and RESET-SLE data
- Cabaletta Bio: Buy Rating Reiterated as Rese-cel Data and Cellares Partnership Support Unchanged $16 Price Target
- Cabaletta Bio, Cellares report 10-year commercial supply agreement for rese-cel
- Cabaletta Bio, Cellares enter 10-year commercial agreement